| Literature DB >> 29616085 |
Dimitrios Baltzis1,2, Evangelia Meimeti3, Maria G Grammatikopoulou4, Matthieu Roustit5, Eleni Mavrogonatou6, Dimitris Kletsas6, Smaragda Efraimidou7, Christos Manes1, Taxiarchis K Nikolouzakis8, John Tsiaoussis8, Aristides M Tsatsakis9, Demetrios A Spandidos10, Christina-Maria Trakatelli2, Nikolaos Drakoulis3.
Abstract
Telomerase is the enzyme that maintains telomere length by adding telomeric repeats after each cell division. Numerous metabolic factors such as obesity, insulin resistance or physical inactivity have been associated with shortened telomeres. In the present study, we assessed telomerase activity in diabetic patients having or not foot ulcer. A total of 90 adult patients with type 2 diabetes mellitus (T2DM) were studied. Patients were allocated into two groups according to the absence or presence of active foot ulcers as follows: Νon-ulcer group (N=58) and ulcer group (N=32). Our data revealed that the patients with diabetic ulcers had significantly greater waist circumference and neuropathy disability score, while exhibiting lower telomerase activity, indicating the possible existence of a common clinical profile among ulcer-bearing diabetic patients. Validation of our findings by extending the study in larger patient groups may contribute to the understanding of T2DM pathophysiology and its main clinical implications.Entities:
Keywords: diabetic peripheral neuropathy; neuropathy disability score; oxidative damage; telomere-diabetes
Year: 2018 PMID: 29616085 PMCID: PMC5876498 DOI: 10.3892/etm.2018.5798
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Clinical charasteristics of participants allocated to two groups according to the absence or presence of diabetic ulcers.
| Characteristic | Total (N=90) | Non-ulcer (N=58) | Ulcer (N=32) | P-value[ |
|---|---|---|---|---|
| Age (years) | 66.0±9.2 | 65.3±9.3 | 67.4±8.8 | 0.2936 |
| Sex (M/W) | 55/35 | 35/23 | 20/12 | |
| Diabetes duration (years) | 14.0±1.0 | 12.0±1.2 | 16.0±1.3 | 0.0683 |
| Waist circumference (cm) | 109.1±12.7 | 107.1±13.2 | 112.8±10.8 | 0.0382 |
| BMI (kg/m2) | 31.3±0.7 | 30.8±0.8 | 31.2±1.0 | 0.0674 |
| Smoking history (Y/N) | 17/73 | 12/46 | 5/27 | |
| TC (mg/dl) | 181.3±39.0 | 181.8±34.4 | 176.6±44.1 | 0.8702 |
| TG (mg/dl) | 127.0±7.8 | 116.5±9.5 | 121.0±10.3 | 0.5722 |
| HDL (mg/dl) | 43.0±1.1 | 44.0±1.2 | 44.0±1.7 | 0.4887 |
| LDL (mg/dl) | 103.5±3.7 | 102.5±3.9 | 105.0±5.3 | 0.8232 |
| HbA1c (%) | 7.1±0.1 | 7.1±0.1 | 7.1±0.2 | 0.2672 |
| Creatinine (mg/dl) | 0.9±0.1 | 0.9±0.1 | 0.9±0.0 | 0.9696 |
| NDS | 10±0.6 | 5.0±0.7 | 11.0±0.5 | 9.09×10−8 |
| Telomerase activity (AU) | 1,275.2±156.8 | 1,573.3±219.7 | 1,146.7±175.5 | 0.0261 |
Estimated with the parametric Tukey's test or the non-parametric Kruskal-Wallis test for normally and not normally distributed variables, respectively. BMI, body mass index; TC, total cholesterol; TG, triglycerides; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NDS, neuropathy disability score; AU, arbitrary units.
Figure 1.Scatter plots showing all values of clinical parameters investigated in this study for the non-ulcer and ulcer group of T2DM patients. In each graph, dots represent distinct values and horizontal line represents the mean or median, depending on the normality or not of the distribution, respectively. T2DM, type 2 diabetes mellitus; BMI, body mass index; TC, total cholesterol; TG, triglycerides; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NDS, neuropathy disability score; AU, arbitrary units.